医学
冲程(发动机)
闭塞
缺血性中风
血管内治疗
心脏病学
内科学
外科
缺血
动脉瘤
机械工程
工程类
作者
Charlotte Zerna,Johanna M. Ospel,Emma Harrison,Timothy Kleinig,Volker Puetz,Daniel Kaiser,Brett Graham,Amy Yu,Brian van Adel,Jai Shankar,Ryan McTaggart,Vítor Mendes Pereira,Donald Frei,Mayank Goyal,Michael D. Hill
出处
期刊:Stroke
[Lippincott Williams & Wilkins]
日期:2025-01-30
卷期号:56 (Suppl_1)
标识
DOI:10.1161/str.56.suppl_1.wp259
摘要
Background and Purpose: To compare the benefit of endovascular treatment (EVT) in acute ischemic stroke (AIS) patients with large vessel occlusion (LVO) presenting >6 hours from last known well outside a clinical trial setting to best medical management and to EVT in a randomized trial setting. Methods: Data from a retrospective multicenter cohort study (ESCAPE LATE) of AIS-LVO patients treated with EVT beyond 6 hours from last known well at former ESCAPE trial sites were pooled with historical data from ESCAPE trial late time window patients. Unadjusted and adjusted 90-day modified Rankin score was compared between ESCAPE LATE patients, ESCAPE late time window EVT arm and control arm patients. Results: A total of 249 patients were included in the analysis: 200 ESCAPE LATE patients (for 141 of whom 90-day clinical outcomes were available) and 49 ESCAPE patients, for all of whom clinical outcome data were available (control arm: 20 and EVT arm: 29). Good clinical outcome (modified Rankin Score 0-2 at 90 days) was nominally, albeit not significantly, lower in patients not treated with EVT (5/19[26.3%]) as compared to ESCAPE EVT arm patients (13/29[44.8%] and ESCAPE-LATE patients (66/141[46.8%]). After adjustment, a graded mRS pattern was seen, whereby patients treated with EVT did better as compared to non-treated patients, and those who underwent EVT in the ESCAPE trial had better mRS as compared to those included in ESCAPE-LATE who underwent EVT in clinical routine. Conclusion: Patients presenting beyond 6 hours from last known well who are treated with EVT in a real-world setting show comparable benefit to patients treated in a clinical trial setting.
科研通智能强力驱动
Strongly Powered by AbleSci AI